Is the future clear?
- What new treatments for childhood psoriasis might be coming soon?
- See our timeline representing the evolution of psoriasis treatments to ensure you can bring benefit to children in the future
How can we treat Mia next?
With Mia’s psoriasis uncontrolled despite initial treatment with established biologics, her physician discusses newer treatments which could have a positive impact on her quality of life. The European approval of IL-17 inhibitor secukinumab, in addition to ixekizumab, means another targeted therapy for children is now available. Together with her family, Mia and her physician discuss its potential.
Mia’s treatment with an IL-17 inhibitor demonstrates clear benefit, and she and her family believe that with control of her psoriasis, the future is brighter.
Clinical trials for other targeted biologic therapies are underway, offering more options. If trial results continue to demonstrate benefit, effective and safe treatments made available to children like Mia living with psoriasis can provide further improvements to quality of life. Continue on to see how more treatments are evolving.
Is the future clear for Mia and her skin?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Clinical trials are ongoing for more targeted biologic therapies
The IL-17R inhibitor brodalumab (NCT032408091) is in paediatric clinical trials for psoriasis along with the
IL-23 inhibitors guselkumab (NCT034518512) and tildrakizumab (NCT039977863), and the TNF-a inhibitor certolizumab pegol (NCT041237954).
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Recent data suggests adult treatments are also effective in children
While limited data from clinical trials has been reported, results appear to be consistent, if not better than, adult data.
Professor Paller gives us her summary of the efficacy and safety in children vs adult data.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Having well-controlled psoriasis in paediatric patients will reduce the impact of psoriasis in later life
There is concern that undertreating children may facilitate the ‘psoriatic march’ from severe untreated inflammation in childhood and its associations to cardiovascular morbidity and mortality in adults9.
Professor Vakirlis describes why early treatment is so important.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
References
- Clinicaltrials.gov. Study to assess the long-term safety, tolerability, efficacy of secukinumab in pediatric patients of age 6 to <18 years, with moderate to severe plaque psoriasis. Available at: https://clinicaltrials.gov/ct2/show/NCT03668613. Accessed 14 May 2020.
- Clinicaltrials.gov. Pediatric study in children and adolescents with severe plaque psoriasis. Available at: https://clinicaltrials.gov/ct2/show/NCT02471144. Accessed 14 May 2020.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
of interest
are looking at
saved
next event
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Novartis Pharma AG, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.